# Reparixin in Pancreatic Islet Transplantation

> **NCT01220856** · PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Reparixin

## Key facts

- **NCT ID:** NCT01220856
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-28
- **Primary completion:** 2013-04-30
- **Final completion:** 2013-04-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220856, "Reparixin in Pancreatic Islet Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01220856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*